Nuvectis Pharma Inc (NASDAQ:NVCT) — Market Cap & Net Worth
Market Cap & Net Worth: Nuvectis Pharma Inc (NVCT)
Nuvectis Pharma Inc (NASDAQ:NVCT) has a market capitalization of $718.17 Million ($718.17 Million) as of September 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10525 globally and #2782 in its home market, demonstrating a -2.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nuvectis Pharma Inc's stock price $22.00 by its total outstanding shares 32644066 (32.64 Million). Also see total assets of Nuvectis Pharma Inc for a full breakdown of the balance sheet.
Nuvectis Pharma Inc Market Cap History: 2022 to 2026
Nuvectis Pharma Inc's market capitalization history from 2022 to 2026. Data shows growth from $244.83 Million to $718.17 Million (51.25% CAGR). Also see cash flow conversion of Nuvectis Pharma Inc for how efficiently the company converts equity into cash flow.
Index Memberships
Nuvectis Pharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.65 Trillion | 0.03% | #296 of 976 |
|
NASDAQ Composite
IXIC
|
$42.00 Trillion | 0.00% | #1083 of 3165 |
Weight: Nuvectis Pharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nuvectis Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nuvectis Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check NVCT live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1643.16x
Nuvectis Pharma Inc's market cap is 1643.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $244.83 Million | $149.00K | -$18.79 Million | 1643.16x | N/A |
Competitor Companies of NVCT by Market Capitalization
Companies near Nuvectis Pharma Inc in the global market cap rankings as of September 19, 2026. Review Nuvectis Pharma Inc tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Nuvectis Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Nuvectis Pharma Inc Historical Marketcap From 2022 to 2026
Between 2022 and today, Nuvectis Pharma Inc's market cap moved from $244.83 Million to $ 718.17 Million, with a yearly change of 51.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $718.17 Million | +191.39% |
| 2025 | $246.46 Million | +39.56% |
| 2024 | $176.60 Million | -35.13% |
| 2023 | $272.25 Million | +11.20% |
| 2022 | $244.83 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Nuvectis Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $718.17 Million USD |
| MoneyControl | $718.17 Million USD |
| MarketWatch | $718.17 Million USD |
| marketcap.company | $718.17 Million USD |
| Reuters | $718.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was forme… Read more